Importance of nitric oxide in the control of renal hemodynamics. The kidney vasculature is under tonic control by nitric oxide (NO) and in cortex, NO controls RA and Kf. Systemic NO inhibition leads to systemic hypertension, increases in RE, mediated by Ang II and ET, and direct effects on RA and Kf. The relationship between NO and other vasoconstrictor systems is variable. In the conscious relaxed animal, vasoconstrictor activity is low, yet acute NO inhibition leads to pressor and renal vasoconstrictor reponses. At physiologic levels, FT unexpectedly is a renal vasodilator, possibly via NO generation at RA. When vasoconstrictor activity is high, NO is very important in maintenance of renal perfusion. Chronic L-NAME produces dose dependent systemic and glomerular capillary hypertension and eventual proteinuria and glomerular damage. NO deficiency is key in this process, although the hypertension becomes refractory to L-arginine administration and dependent on Ang II and the SNS, by mechanisms not yet defined. In contrast, the renal vasculature remains fully responsive to L-arginine, suggesting that pressor and renal vascular responses to chronic NO inhibition are separately regulated. NO generated from iNOS does not normally control BP or renal hemodynamics. The relative contributions of NO from bNOS and eNOS, and importance of NOS in different locations in the kidney, remain to he determined.
Nitric oxide (NO) is a simple messenger molecule, made from L-argininc by the enzymatic action of several nitric oxide synthases (NOS). The different isoforms of NOS are widely distributed. The brain type NOS, bNOS and the vascular endothelial, eNOS are constitutively expressed enzymes. The macrophage inducible NOS, iNOS, is induced in high quantities by immunological stimulation [1] , although there may be a basal "constitutive" expression of iNOS in some locations [2] . Vascular tone is partly controlled by NO generated from eNOS, activated by shear stress [1] . The bNOS is more abundant and widely distributed than eNOS and both central and peripheral neural activity influences systemic and/or regional vascular tone [1, 3] . Under some pathological conditions, NO generated from vascular iNOS, can cause profound hypotension [1] .
The production of NO is determined by the type and quantity of NOS present and by availability of co-factors and substrate [1] . Several L-arginine analogs inhibit NO synthase [11. Drugs such as N monomethyl L-arginine (L-NMA), and nitro L-arginine methylester (L-NAME), are nonselective NOS inhibitors, whereas glucocorticoids and aminoguanidine preferentially inhibit iNOS [1, 41 . Much of our insight into the physiologic role of NO in control of renal function has been obtained using inhibitors of NO © 1996 by the International Society of Nephrology synthesis, and most of the data discussed below deal with studies employing this approach.
Distribution of NOS in the kidney In the kidney, as elsewhere, the most abundant NOS identified is the bNOS, found in glomeruli and vasculature as well as the macula densa, collecting duct and inner medullary thin limb [5] . Detection of eNOS has been more difficult, although recently eNOS was found in the arcuate and interlobular arteries, afferent arterioles and the glomerulus using RT-PCR [6] . Presumably eNOS is also present throughout the vascular endothelium of the renal circulation, although functional evidence, discussed below, suggests that the efferent arteriolar resistance (RE) is not under tonic NO dependent control [7] . In addition, two structurally distinct iNOS occur constitutively in the rat kidney with a wide distribution, which includes vascular smooth muscle at the juxtaglomerular apparatus and tubule epithelium in various segments [1, 2] . In response to immunological stimuli, iNOS have been reported throughout the tubule, as well as in mesangial cells, vascular endothelial cells, and vascular smooth muscle cells [1] .
NO and renal hemodynamics
Acute studies Systemic NO inhibition. In several species systemic administralion of the non-specific NO inhibitors produces dose dependent increases in BP and RVR with falls in RPF and smaller declines in GFR [1, 8, 9] . As shown in Figure 1 , NOS inhibition in the conscious chronically catheterized rat, produces ---35% increase in BP and -100% increase in RVR, leading to a fall in RPF and a smaller fall in GFR due to an increase in filtration fraction [9] . These effects persist for the duration of NO synthesis inhibition, which is particularly impressive since all buffer mechanisms (which should serve to blunt the effect of loss of one vasoactive control system) are operative in the conscious animal. There are regional differences in the extent to which NO controls the circulation, and the renal vaseulature appears to be particularly sensitive since systemic infusion of low doses of NOS inhibitors, which have no effect on BP, and intrarcnal administration of NOS inhibitors, produce increased RVR with reductions in RPF [1, 7, 8, 10] .
In vivo glomerular micropuncture studies have shown that systemic NO inhibition causes marked increases in both preglomerular (RA) and efferent arteriolar (Re) resistances, Figure 2 [7, 11]. As a result, glomerular plasma flow falls but SNGFR is relatively protected due to the large rise in glomerular blood pressure (PGC) resulting from the increased BP and RE. In reduced [7, 11] , probably mediated by mesangial cell contraction, since in vitro NO relaxes the glomerular mesangial cell [1] .
Local, intrarenal NO inhibition. Since systemic NO inhibition produces widespread inhibition of NOS and increases in BP, it is difficult to discriminate between direct intrarenal versus indirect effects of NOS inhibition. Local intrarenal inhibition of NO generation causes smaller increases in RVR than are seen during systemic NO inhibition [7, 8] . As shown in Figure 2 , intrarenal NO inhibition increases RA, but has no effect on RE while exhibiting the similar Kf reducing effect seen with systemic NOS inhibition [7] . In vitro studies on isolated microperfused cortical arterioles have supported our in vivo observation that intrarenal generation of NO control RA but not RE in cortical vessels, although in contrast, NOS inhibition constricts both RA and RE of the in vitro juxtamedullary nephron preparation [1. In some situations, the cortical efferent arteriole can make and respond to NO, and NOS has been localized in R as well as RA [1, 5] . The increased RE, seen with systemic NO inhibition when blood pressure rises, is therefore not apparently due to inhibition of locally generated NO, but reflects some secondary phenomena (see below).
NOS is abundant at the juxtaglomerular apparatus and NO generated within the macula densa controls glomerular hemodynamics via the tubuloglomerular feedback (TGF) system, providing a vasodilatory arm of the autoregulatoiy response by blunting influence the myogenic component of autoregulation, but although there is a suggestion that NO contributes to low pressure dilation of RA, renal autoregulatory ability is relatively intact during NO inhibition, although RVR is reset to a higher value [1] . Furthermore, acute NO inhibition reduces inner medullary blood flow and interferes with the pressure natriuresis [13] .
Interactions with other vasoconstrictor systems. As discussed above, acute NO inhibition leads to significant renal vasoconstriction. This vasoconstriction could result either from withdrawal of an active NO vasodilatory stimulus and/or from amplification of underlying vasoconstrictor systems. Below we consider the interactions between NO and other vasoconstrictor control systems.
(a) Angiotensin II. The response to systemic NO inhibition closely resembles the response to angiotensin II (Ang II) infusion [1] . However, blockade of the endogenous Ang II system has no effect on either the pressor or the renal vasoconstrictor response to systemic NO inhibition in the conscious chronically catheterized rat [141, a preparation in which endogenous levels of Ang II are low, and are not tonically controlling renal hemodynamics. When the Ang II system is acutely activated (volume depletion, surgical stress), or when exogenous Ang II levels are raised by infusion, the renal vasoconstrictor response to acute NOS inhibition is greatly amplified by the high level of Ang II [1, 151. The mechanism(s) by which NO and Ang TI interact when Ang II levels are high, is unclear and may involve interactions at the receptor level as well as NO dependent control of Ang II levels via control of renin release [1] .
In the anesthetized animal acutely prepared for micropuncture, some activation of the renin-angiotensin system is inevitable, and we have preliminary micropuncture data that suggest that this activated Ang II does contribute to the glomerular microcirculatory changes seen with systemic NO inhibition [16] . Concomitant Ang TI blockade with losartan attenuates the increases in BP, RA, and particularly RE, and the reduction in Kf seen with systemic NO inhibition (with NMA) alone. Earlier studies by DeNicola, . The data are shown as percent change (%) from control, and are taken from [7] .
Blantz and Gabbai also suggested that endogenous Ang II mediates some of the glomerular hemodynamic responses to acute systemic NO inhibition in the anesthetized animal [17] .
(b) Endothelin. Endothelin (ET) receptors are widely distributed throughout the vasculature, and while there are both ETA and ET receptors in the kidney, recent evidence suggests that ET induced renal vasoconstriction in the normal kidney is via ETa stimulation [18] . Acute systemic NO inhibition both potentiates the vasoconstrictor actions of ET and also enhances the synthesis and release of ET [19] . In the conscious chronically catheterized rat we found that the increases in BP and RVR seen with acute systemic NO synthesis inhibition were attenuated by concomitant inhibition of ET using either the ET converting enzyme inhibitor phosphoramidon or the mixed ET receptor antagonist, bosentan (which blocks both ETA, and ETB receptor subtypes; Fig. 3 ). The falls in RPF and GFR due to acute NO inhibition were not blunted by ET inhibition, suggesting that in the conscious rat, ET inhibition modifies renal hemodynamics secondary to the blunted pressor effect [20] . We also have preliminary data in the anesthetized micropunctured rat, where the pressor, renal vasoconstrictor, and K5 lowering effects of acute systemic NO inhibition (+NMA) are attenuated by ET blockade. Of particular note, the increase in RE is particularly attenuated by ET inhibition [16] . These studies together with the observations with acute Ang II receptor inhibition (see above) suggest that the increase in RE with systemic but not local intrarenal NO inhibition, is the result of secondary effects of ET and Ang II [16] .
In the course of these studies we conducted control experiments investigating the effect of ETA and ET receptor blockade on the renal vasculature in the normal baseline state. As shown in Figure  3 , unexpectedly, blockade of ETA and ET receptors produced a paradoxical constriction of the preglomerular resistance vessels, suggesting that the physiologic action of ET on the glomerular microcirculation is as a vasodilatory agent [21] . Since selective ETA blockade (with BQI 23) has no effect on RA, [21] this atypical vasodilatory response to ET is mediated via the ETu receptor and presumably reflects ETu mediated release of NO and/or POT2.
(c) Sympathetic nervous system (SNS). The role of the SNS in the vasoconstrictor responses to acute NO inhibition is controversial. Some workers report that SNS inhibition (ganglion blockade, pithing, or adrenergic receptor inhibition) has little effect on the increase in BP and RVR seen with acute NO inhibition. In contrast, others report that the hypertension and renal vasoconstrictinn is at least partly due to both central and peripheral sympathetic activation [1] . Recent evidence suggests that the renal vasoconstriction seen during acute systemic NO inhibition is partially the result of increased renal nerve activity [22] . We have recently investigated the effect of chronic bilateral renal denervation on the renal responses to acute systemic NO inhibition and to stimulation of renal NO synthesis with L-arginine infusion [23] . In the conscious unstressed preparation where efferent renal sympathetic nerve activity is low, we found that renal denervation had no impact on the renal hemodynamic responses to either NO inhibition or NO stimulation.
Overall, withdrawal of NO amplifies any vasoconstrictor systems that are currently active. However, in the basal relaxed state, when vasoconstrictor systems are dormant we still see marked renal vasoconstricor responses to acute NO inhibition, suggesting that tonically, NO exerts a direct vasodilatory effect on the renal microcirculation.
Chronic studies
Hemodynamic and structural effects of chronic NO inhibition. It is possible to produce a sustained hypertension by chronic administration of NO inhibitors such as L-NAME. In studies by us, partial NO inhibition for eight weeks in the rat produced moderate, stable hypertension, marked renal vasoconstriction, with constriction of both preglomerular and efferent resistance vessels, as well as reductions in K. Because of the sustained systemic hypertension and increase in R0, glomerular blood pressure is chronically elevated and these rats display moderate proteinuria and histologic evidence of structural damage with a mild increase in focal and segmental glomerular sclerosis [241. In this model only slight falls in GFR are seen. Ribeiro and colleagues used a higher dose of L-NAME in the drinking water, to produce near complete NO inhibition in rats for four to six weeks [25] . This produced severe and sometimes malignant hypertension with widespread structural damage and large falls in GFR. More complete NO inhibition leads to further elevations in P0, which probably contributes to the increased glomerular injury in the more severe models [1, 241, although withdrawal of the growth inhibitory actions of NO [26] may also contribute to the development of glomerular injury.
Mechanisms of the hypertension. (a) Role of NO deficiency. The basis for this hypertension, produced by chronic administration of L-arginine analogs, is clearly NO deficiency and as expected, 24 -hour urinary nitrite plus nitrate excretion (UNOxV; indicative of NO production) is markedly depressed in chronically NO blocked animals [27] . The 24-hour UNOXV do not correlate quantitatively and inversely with the level of hypertension, however, since we have found that administration of very high dose L-NAME produces further increments in BP without further depressing 24-hour UNOXV [28 and unpublished data] .
The response to L-arginine administration alters as the chronic NO inhibition induced hypertension evolves, suggesting that the factors responsible for the maintenance of the hypertension change. L-arginine is the native substrate for NO and competitively inhibits the NO blocking actions of L-NAME. Chronic administration of L-arginine, together with the L-arginine analog, L-NAME, prevents any increase in BP [291, but after one week of chronic L-NAME administration in rats acute L-arginine infusion is only capable of partially reversing the increased BP [25] . As shown in Figure 4 , we have recently reported that after four to five weeks of chronic L-NAME, acute L-arginine has little effect on BP [30] , although remarkably, the kidney vasodilates normally to the NO substrate, with RVR returning to control values. Thus, although there is clearly a major role for NO deficiency in L-NAME induced hypertension, the diminishing ability to reverse the hypertension with L-arginine suggests that simple competitive inhibition of NO production is not the only mechanism. Structural vascular changes (hypertrophy of resistance vessels) may also be involved although other functional hypertensive mechanisms are also apparently activated [31] .
(b) Role of other vasoconstrictor systems. A number of studies have provided clear evidence that Ang II plays a primary role in the pathogenesis of chronic NO inhibition-induced hypertension.
Chronic Ang II inhibition with either receptor antagonists, or converting enzyme inhibitors, ameliorates the hypertension and renal dysfunction and blunts or prevents the arteriolar and glomerular injury seen with chronic NO inhibition [25, 31, 32] .
Despite these findings, acute Ang II blockade alone has little effect on BP or RVR in anesthetized or awake rats with chronic NO inhibition-induced hypertension [33, 31. However, when acute Ang II blockade is combined with al adrenergic blockade in the conscious rat, the BP is almost normalized, whereas RVR remains elevated [31. There is other evidence that alterations in both the central and peripheral sympathetic nervous system are involved in initiation and maintenance of the chronic L-NAME induced hypertension [1, 22, 35] , although the way in which Aug II and the SNS interact is not yet clear. Based on our findings with L-arginine and combined Ang II and csl adrenoceptor blockade, however, it does seem that that the pressor and the renal hemodynamic responses to chronic L-NAME are separately regulated [31. Role of the various NOS isoforms. It is generally anticipated that NO generated from the constitutive endothelial and possible neuronal NOS plays a major role in control of BP and renal hemodynamics. Unfortunately, the L-arginine analogs most widely used to study the effect of chronic NO inhibition are relatively nonspecific and block all NOS isoforms when administered in high doses. We have conducted preliminary studies in which chronic iNOS inhibition has been produced in the normal, conscious chronically catheterized rat, using daily oral aminoguanidine [36] . There are no effects on BP or renal hemodynamics with two weeks of continual iNOS inhibition, suggesting that at least in rats on a normal dietary salt intake, iNOS, wherever located, have little role or control of blood pressure. Studies are currently underway in a number of laboratories, using the selective bNOS inhibitors in order to describe the roles of this isoform in the control of renal hemodynamics. 
